Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia

Tembhare, Prashant R.; Wiestner, Adrian; Marti, Gerald; Degheidy, Heba; Farooqui, Mohammed; Kreitman, Robert J.; Jasper, Gregory A.; Yuan, Constance M.; Liewehr, David; Venzon, David; Stetler-Stevenson, Maryalice
December 2013
American Journal of Clinical Pathology;Dec2013, Vol. 140 Issue 6, p813
Academic Journal
Objectives: Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstay or in preclinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy. Methods: Using the flow cytometric Quantibrite method (BD Biosciences, San Jose, CA) to determine antibodies bound per cell, we quantified the levels of surface expression of CD20, CD22, CD25, and CD52 in CLL cells from 28 untreated patients. Results: The CLL cells in all cases expressed CD20, CD22, and CD52 but 4 (14%) cases were negative for CD25. Although the ranking of levels of expression from highest to lowest was CD52, CD20, CD22, and CD25, the level of antigen expression on any specific case could not be accurately predicted. Conclusions: Quantification of antigens might be useful in evaluating new antigens to target for therapy and may provide a systematic approach to selecting individualized therapy in CLL.


Related Articles

  • Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Cabezudo, E; Matutes, E; Ramrattan, M; Morilla, R; Catovsky, D // Leukemia (08876924);Nov97, Vol. 11 Issue 11, p1909 

    We have investigated the value of both conventional and quantitative flow cytometry to detect minimal residual disease in 21 CLL patients in remission including bone marrow histology: eight in complete remission (CR), 11 in nodular partial remission (nPR) and two in PR. The techniques used were...

  • Rituximab approved for first-line use in chronic lymphocytic leukaemia.  // British Journal of Hospital Medicine (17508460);Apr2009, Vol. 70 Issue 4, p189 

    The article reports on the approval of rituximab for first-line use in chronic lymphocytic leukaemia.

  • Bendamustine beats competitors in CLL.  // PharmacoEconomics & Outcomes News;Apr2014, Vol. 700 Issue 1, p4 

    The article discusses research being done on the economic implications of using bendamustine, alemtuzumab or chlorambucil for chronic lymphocytic leukemia, which references a study by T. Kongnakorn et al. published online on April 4, 2014.

  • Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia. Aurran-Schleinitz, T.; Telford, W.; Perfetto, S.; Caporaso, N.; Wilson, W.; Stetler-Stevenson, M.A.; Zenger, V.E.; Abbasi, F.; Marti, G.E. // Leukemia (08876924);Dec2005, Vol. 19 Issue 12, p2339 

    The article presents a letter to the editor about a study on oncogenic and cellular characterization of chronic lymphocytic leukemia.

  • Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia. Hamblin, T.J. // Drugs;Mar2001, Vol. 61 Issue 5, p593 

    Chronic lymphocytic leukaemia (CLL) is a disease of late middle age and older. The majority of patients are diagnosed because of a lymphocytosis of at least 5 x 10/L on an incidental blood count. It needs to be distinguished from mantle cell lymphoma and splenic marginal zone lymphoma by...

  • Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Fiegl, M.; Stauder, R.; Steurer, M.; Mian, M.; Hopfinger, G.; Brychtova, Y.; Skrabs, C.; Zabernigg, A.; Schmid, F.; Haslbaur, F.; Winder, G.; Walder, A.; Lang, A.; Voskova, D.; Greil, R.; Mayer, J.; Gastl, G. // Annals of Hematology;Feb2014, Vol. 93 Issue 2, p267 

    This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced B-cell chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (B-PLL) to definitely describe the impact of this antibody in clinical routine use. Data were collected from 208...

  • Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. Rossi, Francesca M.; Del Principe, Maria Ilaria; Rossi, Davide; Consalvo, Maria Irno; Luciano, Fabrizio; Zucchetto, Antonella; Bulian, Pietro; Bomben, Riccardo; Dal Bo, Michele; Fangazio, Marco; Benedetti, Dania; Degan, Massimo; Gaidano, Gianluca; Del Poeta, Giovanni; Gattei, Valter // Journal of Translational Medicine;2010, Vol. 8, p23 

    Background: ZAP-70 is an independent negative prognostic marker in chronic lymphocytic leukemia (CLL). Usually, its expression is investigated by flow cytometric protocols in which the percentage of ZAP-70 positive CLL cells is determined in respect to isotypic control (ISO-method) or residual...

  • The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma. Kraus, Teresa S.; Sillings, Christine N.; Saxe, Debra F.; Shiyong Li; Jaye, David L. // American Journal of Clinical Pathology;Aug2010, Vol. 134 Issue 2, p271 

    Flow cytometric immunophenotyping (FCI) aids in the differentiation of chronic lymphocytic leukemia (CLL) from mantle cell lymphoma (MCL); however, overlapping phenotypes may occur. CD11c expression has been reported in up to 90% of CLL cases but has rarely been reported in MCL. Whether CD11c...

  • Association of Reactive Oxygen Species-Mediated Signal Transduction with In Vitro Apoptosis Sensitivity in Chronic Lymphocytic Leukemia B Cells. Palazzo, Adam L.; Evensen, Erik; Huang, Ying-Wen; Cesano, Alessandra; Nolan, Garry P.; Fantl, Wendy J. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Chronic lymphocytic leukemia (CLL) is a B cell malignancy with a variable clinical course and unpredictable response to therapeutic agents. Single cell network profiling (SCNP) utilizing flow cytometry measures alterations in signaling biology in the context of molecular changes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics